X. Causse

X. Causse, L. Hocqueloux, T. Prazuck, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Rare HFE variants are the most frequent cause of hemochromatosis in non‐c282y homozygous patients with hemochromatosis

X. Causse, P. Brissot, H. Hamdi-Rozé, 2016, American journal of hematology.

Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium

X. Causse, O. Chazouilleres, C. Corpechot, 2020, European journal of gastroenterology & hepatology.

Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.

M. Rudler, D. Thabut, X. Causse, 2017, Journal of hepatology.

Increased incidence of Campylobacter enteritis and their quinolone resistance between 2010 and 2015: Results of a French national observatory conducted in 21 general hospitals (CHG).

X. Causse, D. Poisson, B. Denis, 2019, Clinics and research in hepatology and gastroenterology.

Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations

X. Causse, P. Brissot, S. Cunat, 2013, British journal of haematology.

[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients].

X. Causse, J. Legoux, J. Lagasse, 1997, Gastroenterologie clinique et biologique.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

V. de Lédinghen, T. Asselah, D. Thabut, 2021, BMC Infectious Diseases.

Do penicillins really increase the frequency of a rash when given during Epstein-Barr Virus primary infection?

X. Causse, L. Hocqueloux, J. Guinard, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis: a retrospective case–control study

X. Causse, J. Dumortier, L. Spahr, 2018, European journal of gastroenterology & hepatology.

Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries

K. Simon, P. Marcellin, X. Causse, 2014, Journal of viral hepatitis.

Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study).

B. Giraudeau, X. Causse, Y. Bacq, 2005, Gastroenterologie clinique et biologique.

A case of association between hepatocellular carcinoma and porphyria variegata.

X. Causse, Y. Nordmann, J. Germanaud, 1994, Scandinavian journal of gastroenterology.

Interferon‐α2b therapy reduces liver fibrosis in chronic non‐A, non‐B hepatitis: A quantitative histological evaluation

X. Causse, M. Chevallier, P. Chossegros, 1993, Hepatology.

Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study.

X. Causse, M. Chevallier, P. Chossegros, 1991, Journal of hepatology.

Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.

X. Causse, Y. Bacq, F. Lunel, 2003, Journal of hepatology.

Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.

X. Causse, J. Izopet, Y. Bacq, 2000, Journal of hepatology.

Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis – results of a nationwide survey

X. Causse, T. Fontanges, P. Hervio, 2007, Alimentary pharmacology & therapeutics.

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-

P. Marcellin, D. Thabut, F. Carrat, 2017, The lancet. Gastroenterology & hepatology.

Hepatogastroenterologists’ knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey

P. Potier, X. Causse, C. Renou, 2015, European journal of gastroenterology & hepatology.

Revisiting HBV resistance to entecavir with a phenotypic approach.

X. Causse, A. Moreau, C. Gaudy-Graffin, 2020, Antiviral research.

531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE

P. Marcellin, X. Causse, F. Zoulim, 2012 .

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

T. Asselah, P. Marcellin, D. Thabut, 2019, The Lancet.

Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?

X. Causse, A. Pariente, H. Hagège, 2014, European journal of gastroenterology & hepatology.

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

X. Causse, P. Rougier, F. Caroli-Bosc, 2008, European journal of cancer.

A randomized controlled trial of ursodeoxycholic acid in patients with alcohol‐induced cirrhosis and jaundice

X. Causse, D. Roulot, F. Oberti, 2003, Hepatology.

Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.

T. Asselah, D. Thabut, F. Carrat, 2021, Clinics and research in hepatology and gastroenterology.

Association d’une cryoglobulinémie virale C à une infection à virus coxsackie

P. Potier, X. Causse, T. Boulain, 2005 .

[Correction of immune thrombocytopenia associated with hepatitis C virus infection after combination therapy with interferon alpha and ribavirin].

X. Causse, M. Ripault, J. Lagasse, 2001, Gastroenterologie clinique et biologique.

[Chronic renal insufficiency (interstitial nephritis) under mesalazine].

X. Causse, J. Legoux, J. Lagasse, 1998, Gastroenterologie clinique et biologique.

Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation

X. Causse, A. Prémaud, P. Marquet, 2020, Transplantation.

[Exocrin pancreatic deficiency revealing an alpha-1-antitrypsin deficiency].

X. Causse, G. Deest, S. Ahmed, 2008, Gastroenterologie clinique et biologique.

[Solitary fibrous liver tumor: clinical, radiological and pathological characteristics].

X. Causse, O. Saint-Marc, A. Heitzmann, 2002, Gastroentérologie Clinique et Biologique.

Recipient Selection for Optimal Utilization of Discarded Grafts in Liver Transplantation

X. Causse, P. Bucur, A. Tellier, 2018, Transplantation.

Minimally invasive management of insulinomas

X. Causse, R. Pidoto, A. Cogliandolo, 2001, Surgical Endoscopy.

Minimally invasive management of insulinomas. A case report.

X. Causse, R. Pidoto, A. Cogliandolo, 2001, Surgical Endoscopy.

Baveno-VI-Guided Prediction of Esogastric Varices in Primary Biliary Cholangitis.

X. Causse, O. Chazouilleres, C. Corpechot, 2019, The American journal of gastroenterology.

[A periampullary tumor].

X. Causse, E. Miquelestorena-Standley, C. Bonneau, 2013, Annales de pathologie.

Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study

X. Causse, T. Decaens, J. Seitz, 2018, Cancer.

Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.

V. de Lédinghen, R. Amathieu, M. Rudler, 2015, Journal of hepatology.

[Radiation protection of operators during endoscopic retrograde cholangiopancreatography].

X. Causse, J. Germanaud, R. Sabattier, 1993, Gastroenterologie clinique et biologique.

Disposal of injection material used for the treatment of hepatitis C: comparison with insulin-dependent diabetes and thromboembolism.

B. Giraudeau, X. Causse, L. D'alteroche, 2005, Gastroenterologie clinique et biologique.

P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

P. Marcellin, X. Causse, F. Zoulim, 2014 .

[Hepatic splenosis: a rare etiology of hepatic nodules].

X. Causse, É. Carpentier, C. Bonneau, 2008, Gastroenterologie clinique et biologique.

Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).

X. Causse, C. Renou, A. Pariente, 2019, Presse medicale.

[766] NON INVASIVE TESTS OF LIVER FIBROSIS IN NAFLD

X. Causse, F. Laine, Y. Deugnier, 2007 .

Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN study group.

Zheng Wang, Hong Zhang, C. Clavel, 2023, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Prevalence of antibodies to hepatitis a virus in health care workers

X. Causse, J. Germanaud, J. Barthez, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings

V. de Lédinghen, T. Asselah, X. Causse, 2022, Journal of Hepatology.

An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study)

X. Causse, D. Ouzan, P. Sogni, 2022, Health science reports.

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*

P. Marcellin, F. Carrat, X. Causse, 2015 .

[Strategy of vaccination against hepatitis A].

X. Causse, J. Germanaud, 1993, Presse medicale.

More Reasons for Hope in the Therapy of Chronic Hepatitis C

X. Causse, M. Chevallier, N. Manabe, 1994 .

[Extra-hepatic manifestations of viral hepatitis].

X. Causse, J. Germanaud, J. Legoux, 1995, La Revue du praticien.

585 A FRENCH MULTICENTRIC LONGITUDINAL DESCRIPTIVE STUDY OF HEPATOCELLULAR CARCINOMA MANAGEMENT (THE CHANGH COHORT): PRELIMINARY RESULTS

X. Causse, T. Decaens, C. Renou, 2010 .

The occupational risk of hepatitis C infection among hospital employees.

X. Causse, J. Germanaud, J. Barthez, 1994, American Journal of Public Health.

Clinics and research in hepatology and gastroenterology

ScienceDirect, M. Rudler, X. Causse, 2011 .

Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)

V. de Lédinghen, A. Mangia, X. Causse, 2023, Journal of Hepatology.

HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

V. de Lédinghen, T. Asselah, X. Causse, 2023, Journal of Hepatology.